Who has experience with protein and oligonucleotide QC analysis und inhaled drug products under one roof?

Big Pharma and Biotech’s are looking at alternative routes of  dministration for proteins (e.g., monoclonal antibodies) and oligonucleotides (e.g. Antisense Oligonucleotides) to treat diseases of the respiratory tract.

A plethora of well-established inhalation devices and formulation technologies can be optimized to enable the aerosolization of proteins and oligonucleotides, at the same time not impacting the structures of these entities and maintaining efficacy.

Traditionally, small molecules have been dominating the market of inhaled drugs. Therefore, contract testing organizations specialized in testing these drugs mostly have labs, capable of testing small molecules.